Flynn acquired the marketing rights for Circadin (prolonged release melatonin) in the UK and Ireland from Neurim Pharmaceuticals. Circadin is used for the teatment of primary insomnia in the over 55 age range.
An experienced hospital team of hospital specialists has been deployed along with a dedicated brand manager.
Circadin is a patent-protected 2mg prolonged-release melatonin formulation. For more detailed information about the product click here.
There is also a patient support site for insomnia and sleep disorders called ‘Sleep Well Live Well’. This site provides information about common sleep disorders, symptoms and treatments, and also provides a sleep diary plus other interactive tools.